Clinical trials: CRC
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT05600309
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 24 sites in China
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)
This study will test the effectiveness of mailing fecal immunochemical tests (FITs) in increasing colorectal cancer (CRC) screening rates in U.S. adults ages 45-75.
- Trial name
- SCORE (NCT04406714)
- Testing
- Trial Mailed FIT Intervention - Age Group 50-75, Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49, Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49
- Where
- 2 sites in United States
- Volunteers
- 4,318 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Tumors, Colorectal Neoplasms
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
Background: Colorectal cancer is a common cancer in the Unites States (U.S.) It causes the second most cancer-related deaths. The drug avelumab and vaccine Ad-CEA together help the immune system fight cancer.
- Conditions
- Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT03050814
- Testing
- Avelumab, Ad-CEA vaccine, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification
- Trial name
- NCT04096417
- Testing
- Pemigatinib, Quality-of-Life Assessment
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
Improving Colorectal Cancer Screening in Racially Diverse Zip Codes Using Navigation and Machine Learning (PCSNaP)
The overarching goal of the "PCSNaP" Research Study is to support the Abramson Cancer Center (ACC) of the University of Pennsylvania in carrying out its mission to increase colorectal cancer (CRC) screening completion among…
- Trial name
- PCSNaP (NCT05383976)
- Testing
- Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program
- Where
- United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Colorectal Cancer
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00613080
- Testing
- capecitabine, oxaliplatin, resection
- Where
- 120 sites in United States, Canada
- Volunteers
- 79 people
- Sponsor
- Radiation Therapy Oncology Group
Colorectal Cancer
U01 CRC Project for Vietnamese Americans
Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third highest cause of mortality in Vietnamese and Asian Americans.
- Trial name
- NCT03413605
- Testing
- A Multilevel CBPR Intervention
- Where
- 2 sites in United States
- Volunteers
- 801 people
- Sponsor
- Temple University
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Adenoma, Colorectal Carcinoma
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT02965703
- Testing
- Aspirin, Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Screening
Feasibility of a Colorectal Cancer Screening Web App in Primary Care Patients
The goal of this clinical trial is to test the feasibility of a web app about colorectal cancer screening in patients with an upcoming primary care appointment.
- Trial name
- NCT06241768
- Testing
- mPATH-CRC Web app
- Where
- United States
- Volunteers
- 921 people
- Sponsor
- Digital Health Navigation Solutions, Inc
Metastatic Colorectal Adenocarcinoma
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC).
- Trial name
- NCT03043313
- Testing
- Trastuzumab, Tucatinib
- Where
- 56 sites in United States, Belgium and 3 more
- Volunteers
- 117 people
- Sponsor
- Seagen Inc.
Hepatocellular Carcinoma, Hepatocellular Cancer
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03785210
- Testing
- nivolumab, tadalafil, oral vancomycin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of…
- Trial name
- NCT01057017
- Testing
- intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brown University
Familial Adenomatous Polyposis
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Primary Objective: To determine whether celecoxib downregulates GATA-6 expression to upregulate 15-LOX-1 expression and induce apoptosis in human rectal tumors, researchers will measure GATA-6 and 15-LOX-1 expression, 13-S-HODE…
- Trial name
- NCT00503035
- Testing
- Celecoxib, Colonoscopy Biopsy
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Liver Neoplasms, Colonic Neoplasms
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
The purpose of this study is to determine a tolerable dose of radiation delivered by the CyberKnife system in two groups of patients with hepatocellular carcinoma (HCC).
- Conditions
- Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
- Trial name
- NCT01528878
- Testing
- Stereotactic Radiosurgery using the CyberKnife System.
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center